Anti-estrogenic therapies can suppress the growth of cancer that does not express estrogen receptors; when combined with immune checkpoint inhibitor therapies, they halt tumor progression in mice ...
Until recently, most women who underwent adjuvant hormone therapy to reduce the chance of a breast cancer recurrence took tamoxifen every day for 5 years. However, with the advent of newer hormone ...
Hormone receptor–positive, human epidermal growth factor 2 (HER2)–negative metastatic breast cancer (MBC) represents the most common subtype of MBC and has undergone substantial therapeutic evolution.
Anti-estrogenic therapies can suppress the growth of cancer that does not express estrogen receptors; when combined with immune checkpoint inhibitor therapies, they halt tumor progression in mice ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results